Atelerix Life Sciences - Crunchbase Company Profile & Funding

Q: How much funding has Atelerix Life Sciences raised to date?

Atelerix Life Sciences has raised obfuscated.

Overview

Atelerix Life Sciences

Total Funding

obfuscation

Growth Score

Heat Score

Company Performance Metrics

Score

Trend

About These Metrics

AI Content may contain mistakes and is not legal, financial or investment advice.

Learn more.

Growth Score - The measure of growth based on company activity, operational metrics, and investments

Growth Trend - The change in the growth score over the given time period

Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity

Heat Trend - The change in the heat score over the given time period

Recent Milestones

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

See more interactive data and historical milestones on desktop for the best experience

About Atelerix Life Sciences

CB Rank

116512

Atelerix Life Sciences is a biotechnology company developing cutting-edge proprietary small molecules for the process of addiction.

Founded

obfuscation

Private

Seed

Charlottesville, Virginia, United States

1-10

atelerixlifesciences.com/

Biotechnology

Health Care

Life Science

Therapeutics

Funding Rounds

Seed

OBF

obfuscation

Key People

David G. Kalergis: CEO
James Bates: CMO

Details

Legal Name

Atelerix Life Sciences Inc.

Operating Status

Active

Company Type

For Profit

Founders

Benjamin Gaston, David G. Kalergis, James Bates, Stephen Lewis

About the Company

Atelerix Life Sciences is a biotechnology company developing cutting-edge proprietary small molecules for the process of addiction.

Predictions & Insights

Growth Prediction

See this Growth Prediction

Products & Services

ATLX-0199 (Sudaxine)

A small molecule drug that reverses opioid-induced respiratory depression while preserving pain relief.

ATLX-0190 (D-CYSee)

A small molecule compound targeting respiratory and cardiovascular depression, with potential applications in overdose, addiction, and end-of-life pain control.

Unlock More with Crunchbase Pro

Full access to financial & funding data on unlimited profiles
Export up to 2k results/month for analysis
Track market signals on competitors, products, and R&D
Preview private company insights and predictions

Financials

Company Funding

Funding Rounds

Total Funding Amount

obfuscation

Number of Funding Rounds

Unlock company funding data, including rounds, dates, amounts, and investors.

Announced Date	Transaction Name	Number of Investors	Money Raised	Lead Investors	Funding Type
obfuscated obfuscation	Seed Round - Atelerix Life Sciences	—	obfuscated obfuscation	—	Seed
obfuscated obfuscation	Seed Round - Atelerix Life Sciences	—	obfuscated obfuscation	—	Seed
obfuscated obfuscation	Seed Round - Atelerix Life Sciences	—	obfuscated obfuscation	—	Seed
obfuscated obfuscation	Seed Round - Atelerix Life Sciences	—	obfuscated obfuscation	—	Seed
obfuscated obfuscation	Seed Round - Atelerix Life Sciences	—	obfuscated obfuscation	—	Seed

Funding Rounds

Total Funding Amount

obfuscation

Number of Funding Rounds

Unlock company funding data, including rounds, dates, amounts, and investors.

Announced Date	Transaction Name	Number of Investors	Money Raised	Lead Investors	Funding Type
obfuscated obfuscation	Seed Round - Atelerix Life Sciences	—	obfuscated obfuscation	—	Seed
obfuscated obfuscation	Seed Round - Atelerix Life Sciences	—	obfuscated obfuscation	—	Seed
obfuscated obfuscation	Seed Round - Atelerix Life Sciences	—	obfuscated obfuscation	—	Seed
obfuscated obfuscation	Seed Round - Atelerix Life Sciences	—	obfuscated obfuscation	—	Seed
obfuscated obfuscation	Seed Round - Atelerix Life Sciences	—	obfuscated obfuscation	—	Seed